TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15812582

Group type: EXPERIMENTAL
Intervention: Active group (screening visit with lifestyle questionnaire and quantitative ultrasound heel scan)
Number of subjects: 5306

Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 5306

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5306
Study: 11570381

Group type: EXPERIMENTAL
Intervention: Maze procedure with SICTRA (20 to 32 W; 200 to 320 mL/h saline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Maze procedure with SICTRA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (without Maze procedure)
Number of subjects: 30
Study: 9551875

Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg once daily
Number of subjects: 231

Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 231
Study: 7941939

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.5% 2.5 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no epidural bupivacaine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 30
Study: 2896555

Group type: EXPERIMENTAL
Intervention: ICI 118,551 10 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: ICI 118,551 20 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: ICI 118,551 50 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: ICI 118,551 100 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 29569254

Group type: EXPERIMENTAL
Intervention: BMMC (bone marrow-derived mononuclear cells)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: BMMC
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: BMMC and Placebo
Number of subjects: 121
Study: 27382814

Group type: EXPERIMENTAL
Intervention: Pentazocine with rectal diclofenac (100mg diclofenac suppository and 30mg intramuscular pentazocine)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Pentazocine alone (30mg intramuscular pentazocine)
Number of subjects: 130
Study: 24831517

Group type: EXPERIMENTAL
Intervention: Effective antiretroviral therapy (ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initiation of ART within six months of infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low CD4/CD8 ratio during effective ART
Number of subjects: 0
Study: 21797916

Group type: COMPARATOR
Intervention: Placebo transdermal gel and placebo pills
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 10 g/day plus placebo pills
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 10 g/day plus the aromatase inhibitor anastrozole 1 mg/day
Number of subjects: 22
Study: 20433732

Group type: EXPERIMENTAL
Intervention: VAS version of the WOMAC scale
Number of subjects: 221
Study: 18054753

Group type: EXPERIMENTAL
Intervention: Combination treatment of 32-week peginterferon alfa-2b and 2-year lamivudine
Number of subjects: 26
Study: 15607598

Group type: EXPERIMENTAL
Intervention: Moderate systemic hypothermia (33 degrees C) for 48 hours
Number of subjects: 65

Group type: COMPARATOR
Intervention: Normothermia (37 degrees C) for 48 hours
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Combined outcome of death or severe motor scores
Number of subjects: 65
Study: 12169076

Group type: EXPERIMENTAL
Intervention: Hand-rubbing protocol with 75% aqueous alcoholic solution containing propanol‐1, propanol‐2, and mecetronium etilsulfate
Number of subjects: 4387

Group type: COMPARATOR
Intervention: Hand-scrubbing protocol with antiseptic preparation containing 4% povidone iodine or 4% chlorhexidine gluconate
Number of subjects: 4387

Group type: EXPERIMENTAL
Intervention: Hand-rubbing protocol
Number of subjects: 4387

Group type: COMPARATOR
Intervention: Hand-scrubbing protocol
Number of subjects: 4387
Study: 10869895

Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/d)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 8808415

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention program (2.5-hr, 10-week activity-based program)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (administered questionnaires only)
Number of subjects: 35
Study: 2062513

Group type: EXPERIMENTAL
Intervention: Modified Airlie House classification for diabetic retinopathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double grading system with adjudication of disagreements
Number of subjects: 0
Study: 6668531

Group type: EXPERIMENTAL
Intervention: Half-sitting position
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 100
Study: 30696660

Group type: EXPERIMENTAL
Intervention: Exercise at home (73% preference) using a combination of aerobic and resistance training (41%)
Number of subjects: 423
Study: 29664801

Group type: EXPERIMENTAL
Intervention: Rectal Cancer Female Sexuality score (development and validation)
Number of subjects: 466
Study: 27107810

Group type: EXPERIMENTAL
Intervention: Running schedule emphasizing intensity (Schedule-I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Running schedule emphasizing volume (Schedule-V)
Number of subjects: 0
Study: 25139726

Group type: EXPERIMENTAL
Intervention: Assisted exercise
Number of subjects: 120

Group type: COMPARATOR
Intervention: Voluntary rate cycling
Number of subjects: 120
Study: 20960028

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day, Schedule 2/1) + Pemetrexed (500 mg/m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg/day, continuous daily dosing) + Pemetrexed (500 mg/m2)
Number of subjects: 12
Study: 19251868

Group type: EXPERIMENTAL
Intervention: First episode of major depression (MD)
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: Recurrent major depression (MD)
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Non-depressed patients
Number of subjects: 1328
Study: 17490489

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg once daily for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bendroflumethiazide 2.5 mg once daily for 12 weeks
Number of subjects: 120
Study: 15658072

Group type: EXPERIMENTAL
Intervention: 2 mg of intranasal butorphanol (treatment B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 mg of intranasal butorphanol (treatment C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 mg of i.v. butorphanol (treatment A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intranasal butorphanol (1 mg and 2 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All treatments (1 mg, 2 mg intranasal, and 2 mg i.v.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 24
Study: 11055460

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg per dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.6 mg/kg per dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg and 0.6 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9135403

Group type: COMPARATOR
Intervention: Disodium cromoglycate 4% (DSCG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1%
Number of subjects: 30
Study: 8398318

Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide 100 mg orally days 1‐14, methotrexate 50 mg i.v. days 1 and 8, 5‐fluorouracil 1 g i.v. days 1 and 8, repeating at 28‐day intervals for six courses)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: MMM (mitozantrone 8 mg/m2 i.v. once every 3 weeks, methotrexate 50 mg i.v. once every 3 weeks, mitomycin C 8 mg/m2 once every 6 weeks, for 8 courses)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Infusional FEC (5‐fluorouracil 200 mg/m2 i.v. 24 hourly by continuous infusion for 6 months, epirubicin 50 mg/m2 i.v. bolus once every 3 weeks for 6 months, cisplatin 60 mg/m2 i.v. once every 3 weeks for 6 months)
Number of subjects: 84
Study: 2946552

Group type: EXPERIMENTAL
Intervention: Monophasic desogestrel plus EE
Number of subjects: 34

Group type: COMPARATOR
Intervention: Triphasic levonorgestrel plus EE
Number of subjects: 34
Study: 3131943

Group type: EXPERIMENTAL
Intervention: 40 mg mitomycin C (MMC) instilled for 0.5 hours
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 40 mg mitomycin C (MMC) instilled for 1.0 hours
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 40 mg mitomycin C (MMC) instilled for both 0.5 and 1.0 hours
Number of subjects: 31
Study: 30548528

Group type: EXPERIMENTAL
Intervention: Low PR-A in endometrial glands
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Low PR-A in stroma
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: High PR-B in endometrial glands
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: PR-A:PR-B ratio ≤ 1
Number of subjects: 135
Study: 29136032

Group type: EXPERIMENTAL
Intervention: 2NRTI+NNRTI long-term ART with CD4 monitoring
Number of subjects: 1206

Group type: COMPARATOR
Intervention: 2NRTI+NNRTI long-term ART without CD4 monitoring
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Children with VL rebound ≥5,000 copies/ml
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Children with VL 1,000-5,000 copies/ml
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: NRTI resistance
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Overall study findings
Number of subjects: 1206
Study: 25176942

Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS ON)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control (VNS OFF)
Number of subjects: 96
Study: 23238489

Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Face-to-face assessment
Number of subjects: 15
Study: 21986346

Group type: EXPERIMENTAL
Intervention: 5-session manual-based, educator-led structured group intervention with cognitive behavioral strategies
Number of subjects: 222

Group type: COMPARATOR
Intervention: Educator-led attention control group education program
Number of subjects: 222

Group type: COMPARATOR
Intervention: Unlimited individual nurse and dietitian education sessions for 6 months
Number of subjects: 222
Study: 17961560

Group type: EXPERIMENTAL
Intervention: 100 microg/day E(2) patch, oral medroxyprogesterone acetate 10 mg for 12 days each month for patients
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (regularly menstruating women)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Patients with testosterone levels below normal
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Patients with primary ovarian insufficiency
Number of subjects: 143
Study: 16930358

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levetiracetam 2000 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17129331

Group type: EXPERIMENTAL
Intervention: Nurse practitioners (NPs) as consultants performing basic incontinence evaluation and treatment for 16 weeks
Number of subjects: 320

Group type: COMPARATOR
Intervention: Nurse practitioners (NPs) as consultants performing basic incontinence evaluation and treatment
Number of subjects: 320
Study: 10654503

Group type: EXPERIMENTAL
Intervention: Coronary revascularization with normothermic cardiopulmonary bypass
Number of subjects: 52

Group type: COMPARATOR
Intervention: Coronary revascularization without normothermic cardiopulmonary bypass
Number of subjects: 52
Study: 9062610

Group type: EXPERIMENTAL
Intervention: metoclopramide 0.15 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: saline 0.03 ml/mg
Number of subjects: 30
Study: 8356168

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine mesylate (DHE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propentofylline (PPF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lisuride maleate (LIS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibudilast (IDL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nicergoline (NCG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3746952

Group type: EXPERIMENTAL
Intervention: MAST (163 patients)
Number of subjects: 352

Group type: COMPARATOR
Intervention: No-MAST (189 patients)
Number of subjects: 352
Study: 31194979

Group type: EXPERIMENTAL
Intervention: Proactive monitoring (trough concentrations measured at weeks 4 and 8 and then every 8 weeks until week 72, n = 38)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Proactive monitoring
Number of subjects: 78

Group type: COMPARATOR
Intervention: Reactive monitoring (physicians informed of trough concentrations after loss of response, n = 40)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Reactive monitoring
Number of subjects: 78
Study: 26924839

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26598458

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: sIgE measurements for cow's milk, egg white, peanut, wheat, seafood mix, and soybean
Number of subjects: 1000
Study: 23650892

Group type: EXPERIMENTAL
Intervention: Mild ipsilateral head rotation to >30° left position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mild ipsilateral head rotation to <30° right position
Number of subjects: 40
Study: 20608995

Group type: EXPERIMENTAL
Intervention: Pravastatin at 10 mg/day (PRAVA, n = 12)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rosuvastatin at 2.5 mg/day (ROSUVA, n = 11)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-statin group (n = 13)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pravastatin and VHD
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rosuvastatin and Non-statin
Number of subjects: 50
Study: 18270387

Group type: EXPERIMENTAL
Intervention: Grading of anterior knee laxity by certified athletic trainers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Instrumented measurements of anterior tibial translation using MEDmetric KT1000 knee ligament Arthrometer
Number of subjects: 12
Study: 16569825

Group type: EXPERIMENTAL
Intervention: Gatifloxacin monotherapy
Number of subjects: 266

Group type: COMPARATOR
Intervention: Clarithromycin alone or combined with ceftriaxone
Number of subjects: 266

Group type: COMPARATOR
Intervention: Clarithromycin with ceftriaxone
Number of subjects: 266
Study: 14504894

Group type: EXPERIMENTAL
Intervention: Combined cataract operation
Number of subjects: 116

Group type: COMPARATOR
Intervention: No simultaneous operation (control)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both groups (combined cataract operation and no simultaneous operation)
Number of subjects: 116
Study: 11207516

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg), clarithromycin (250 mg), metronidazole (400 mg) given twice daily for 1 week
Number of subjects: 180

Group type: COMPARATOR
Intervention: Omeprazole (20 mg), clarithromycin (250 mg), metronidazole (400 mg) given twice daily for 1 week
Number of subjects: 180
Study: 9049575

Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 30 micrograms.kg‐1.min‐1 (group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 5 micrograms.kg‐1.min‐1 (group II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 2 micrograms.kg‐1.min‐1 (group III)
Number of subjects: 0
Study: 8103646

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2873396

Group type: EXPERIMENTAL
Intervention: Cyclosporin 7.5 mg/kg per day
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 31910992

Group type: COMPARATOR
Intervention: Lower target glycemic control (80-100 mg/dL)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Higher target glycemic control (150-180 mg/dL)
Number of subjects: 214
Study: 28455159

Group type: EXPERIMENTAL
Intervention: cSEMSs (fully covered self-expandable metal stents) for 6 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: MPSs (multiple plastic stents) exchanged every 3 months over 1 year
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: cSEMSs
Number of subjects: 64

Group type: COMPARATOR
Intervention: MPSs
Number of subjects: 64
Study: 28232046

Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 499

Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 499
Study: 26825666

Group type: EXPERIMENTAL
Intervention: Probiotic capsule containing four bacterial strains
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 64
Study: 23742669

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy (PDT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 66
Study: 21959480

Group type: EXPERIMENTAL
Intervention: Acetaminophen (40 mg/kg) plus diclofenac (1 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acetaminophen (40 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diclofenac (1 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 18240925

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) + physical therapy (PT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Physical therapy (PT) alone
Number of subjects: 54
Study: 17361530

Group type: EXPERIMENTAL
Intervention: General anaesthesia with combination of acupuncture (HANS) and enflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enflurane alone
Number of subjects: 60
Study: 14663804

Group type: EXPERIMENTAL
Intervention: Histoacryl glue and minimal number of interrupted resorbable sutures
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (gelatin sponge and multiple interrupted resorbable sutures)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Negative control group (patients who had never been on anticoagulant therapy)
Number of subjects: 30
Study: 10822433

Group type: EXPERIMENTAL
Intervention: Robotic training (at least 25 hours)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Exposure to the robotic device without training
Number of subjects: 56
Study: 8877668

Group type: EXPERIMENTAL
Intervention: Mouthrinses containing salifluor
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.12% salifluor mouthrinse
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthrinse
Number of subjects: 10
Study: 1649005

Group type: EXPERIMENTAL
Intervention: 1.3% pyrophosphate/1,100 ppm F/1.5% Gantrez dentifrice
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1,100‐ppm F dentifrice without pyrophosphate or Gantrez
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrices (both types)
Number of subjects: 15
Study: 6137980

Group type: COMPARATOR
Intervention: suxamethonium (group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: suxamethonium (group D)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: vecuronium (group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: vecuronium (group C)
Number of subjects: 52

Group type: COMPARATOR
Intervention: suxamethonium
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: vecuronium
Number of subjects: 52
Study: 31899372

Group type: EXPERIMENTAL
Intervention: Oral health community health worker (CHW) intervention delivered in four visits over one year
Number of subjects: 420

Group type: COMPARATOR
Intervention: Usual services (wait-list control)
Number of subjects: 420
Study: 31430830

Group type: EXPERIMENTAL
Intervention: Single-session Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 54
Study: 28174351

Group type: EXPERIMENTAL
Intervention: Probiotic soy milk containing Lactobacillus plantarum A7
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional soy milk
Number of subjects: 44
Study: 26075381

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) and Acceptance and commitment therapy (ACT)
Number of subjects: 135
Study: 23562184

Group type: EXPERIMENTAL
Intervention: Morning blue-light exposure (λmax=470 nm)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Morning dim-light exposure
Number of subjects: 21
Study: 21968863

Group type: EXPERIMENTAL
Intervention: Souvenaid (medical food)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iso-caloric control product
Number of subjects: 0
Study: 19066607

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin (arm A)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Gemcitabine/vinorelbine (arm B)
Number of subjects: 92
Study: 17287679

Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting phosphorylcholine polymer-coated stent (n=598)
Number of subjects: 1197
Study: 14749563

Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.1 mg/kg by mouth twice daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 11273789

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg orally, twice daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9624308

Group type: EXPERIMENTAL
Intervention: 10 mg sublingual melatonin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8895290

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV (Group O)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Droperidol 0.625 mg IV plus Metoclopramide 10 mg IV (Group DM)
Number of subjects: 200
Study: 2270942

Group type: EXPERIMENTAL
Intervention: Standard metre rod for accuracy check
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Two experienced observers measuring height
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Non-blind and non-randomised measurements
Number of subjects: 240
Study: 7373324

Group type: EXPERIMENTAL
Intervention: Oxiperomide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10